HeartFlow has launched the next-generation interactive HeartFlow Plaque Analysis platform, which is designed to enhance clinical decision-making in assessing patient risk in suspected coronary artery disease (CAD).
The advanced tool integrates with FFRᴄᴛ to offer a comprehensive view of a patient’s plaque burden, enabling personalised treatment plans.
Go deeper with GlobalData
The new HeartFlow Plaque Analysis platform provides clinicians with a non-invasive solution to quantify and characterise plaque in the coronary arteries.
By analysing CT angiogram (CCTA) scans, the platform creates a detailed 3D model of the arteries, offering insights into the volume and type of plaque present.
The integration of plaque quantification with lesion-specific FFRᴄᴛ values is a key feature of the interactive experience.
It presents a 3D plaque model and comprehensive analysis, covering various plaque types such as calcified, non-calcified, and low attenuation.
The platform allows for displaying cross-sectional, colour-coded images of each plaque type along the vessel.
HeartFlow said the Plaque Analysis is recognised for its high level of accuracy, with a 95% agreement for total plaque volume measures when compared to the gold standard IVUS.
HeartFlow chief medical officer Campbell Rogers said: “Accurately diagnosing a patient’s risk for coronary artery disease is critical for determining the best treatment. Our new interactive plaque experience marks an exciting era in AI-enabled cardiac technology, where we are now the only company that offers a fully integrated view of a patient’s true burden of coronary artery disease.
“The elevated visualisation of Plaque Analysis integrated with our flagship FFRᴄᴛ Analysis, sets HeartFlow apart as a wholistic solution for CT analysis, enabling physicians to enhance personalised treatment decisions.”
